Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
Open Access
- 3 May 2016
- Vol. 122 (14), 2178-2185
- https://doi.org/10.1002/cncr.30031
Abstract
BACKGROUND Older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia (r/r ALL) are reported to have a poor prognosis and few therapeutic options. In the current study, the authors evaluated treatment with single‐agent blinatumomab in adults aged ≥65 years with r/r ALL. METHODS A total of 261 adults with r/r ALL who were examined across two phase 2 studies received blinatumomab in cycles of 4‐week continuous infusion and 2‐week treatment‐free intervals. The primary endpoint in each study was complete remission (CR) or CR with partial hematologic recovery (CRh) during the first 2 cycles. Data were pooled and analyzed according to patient age at screening (aged ≥65 years vs aged Cancer 2016;122:2178–85. © 2016 American Cancer Society.Funding Information
- Amgen Inc.
This publication has 25 references indexed in Scilit:
- How I treat older patients with ALLBlood, 2013
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood, 2012
- The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remissionBlood, 2010
- Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemiaCancer, 2008
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008
- In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Blood, 2008
- Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialBlood, 2006
- Results of the PETHEMA ALL‐96 trial in elderly patients with Philadelphia chromosome‐negative acute lymphoblastic leukemiaEuropean Journal of Haematology, 2006
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006
- Acute Lymphoblastic Leukemia: Older Patients and Newer DrugsHematology, 2005